CL4-modified exosomes deliver lncRNA DARS-AS1 siRNA to suppress triple-negative breast cancer progression and attenuate doxorubicin resistance by inhibiting autophagy.
暂无分享,去创建一个
Jie Liu | Ge Zhang | Xiaoxia Chai | Da-Chuan Yin | Xinli Liu | Tongyao Yu | Chen-Yu Zhang | Tong-Yao Yu | Tongyao Yu
[1] Shangyong Li,et al. Co-delivery of doxorubicin and hydroxychloroquine via chitosan/alginate nanoparticles for blocking autophagy and enhancing chemotherapy in breast cancer therapy , 2023, Frontiers in Pharmacology.
[2] K. Witwer,et al. Extracellular vesicles: the next generation in gene therapy delivery. , 2023, Molecular therapy : the journal of the American Society of Gene Therapy.
[3] Jiujie Cui,et al. Prediction of Survival and Tumor Microenvironment Infiltration Based on Pyroptosis-Related lncRNAs in Pancreatic Cancer , 2022, Disease markers.
[4] Jordan J. Green,et al. Polymeric nanoparticles for dual-targeted theranostic gene delivery to hepatocellular carcinoma , 2022, Science advances.
[5] Xiangliang Yang,et al. Extracellular‐Vesicle‐Based Drug Delivery Systems for Enhanced Antitumor Therapies through Modulating the Cancer‐Immunity Cycle , 2022, Advanced materials.
[6] Gang Zhao,et al. Exosomes deliver lncRNA DARS-AS1 siRNA to inhibit chronic unpredictable mild stress-induced TNBC metastasis. , 2022, Cancer letters.
[7] Jeffrey T. Chang,et al. Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] B. Han,et al. Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies , 2022, Journal of Hematology & Oncology.
[9] Xiaolu Yang,et al. Autophagy and pluripotency: self-eating your way to eternal youth. , 2022, Trends in cell biology.
[10] M. Shariati,et al. Exosome-based nanomedicine for cancer treatment by targeting inflammatory pathways: Current status and future perspectives. , 2022, Seminars in cancer biology.
[11] K. Wisinski,et al. Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer , 2022, Cancers.
[12] Zihua Zeng,et al. Aptamer-armed nanostructures improve the chemotherapy outcome of triple-negative breast cancer. , 2022, Molecular therapy : the journal of the American Society of Gene Therapy.
[13] Qiming Wang,et al. DARS-AS1 recruits METTL3/METTL14 to bind and enhance DARS mRNA m6A modification and translation for cytoprotective autophagy in cervical cancer , 2022, RNA biology.
[14] L. Gianni,et al. Treatment landscape of triple-negative breast cancer — expanded options, evolving needs , 2021, Nature Reviews Clinical Oncology.
[15] Hongjie Xiong,et al. Engineered Aptamer-Organic Amphiphile Self-Assemblies for Biomedical Applications: Progress and Challenges. , 2021, Small.
[16] D. Yin,et al. miR-194-Loaded Gelatin Nanospheres Target MEF2C to Suppress Muscle Atrophy in a Mechanical Unloading Model. , 2021, Molecular pharmaceutics.
[17] L. Cerchia,et al. Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors , 2021, Journal of experimental & clinical cancer research : CR.
[18] C. Maher,et al. Long noncoding RNAs in cancer metastasis , 2021, Nature Reviews Cancer.
[19] Fei Chen,et al. Connections between endoplasmic reticulum stress-associated unfolded protein response, mitochondria, and autophagy in arsenic-induced carcinogenesis. , 2021, Seminars in cancer biology.
[20] A. Dash,et al. Liposomes and transferosomes: a breakthrough in topical and transdermal delivery. , 2021, Therapeutic delivery.
[21] Shichao Han,et al. Downregulation of LncRNA DARS-AS1 Inhibits the Tumorigenesis of Cervical Cancer via Inhibition of IGF2BP3 , 2021, OncoTargets and therapy.
[22] Haocai Chang,et al. Targeting autophagy to overcome drug resistance: further developments , 2020, Journal of Hematology & Oncology.
[23] G. Sheng,et al. Oncogenic Long Noncoding RNA DARS-AS1 in Childhood Acute Myeloid Leukemia by Binding to microRNA-425 , 2020, Technology in cancer research & treatment.
[24] I. Berindan‐Neagoe,et al. New perspectives in triple-negative breast cancer therapy based on treatments with TGFβ1 siRNA and doxorubicin , 2020, Molecular and Cellular Biochemistry.
[25] M. Cantile,et al. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer , 2020, Journal of experimental & clinical cancer research : CR.
[26] R. Keri,et al. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene , 2020, Breast Cancer Research.
[27] Xiukun Lin,et al. Exosomes-coated bcl-2 siRNA inhibits the growth of digestive system tumors both in vitro and in vivo. , 2020, International journal of biological macromolecules.
[28] Hui Guo,et al. DARS-AS1 promotes clear cell renal cell carcinoma by sequestering miR-194-5p to up-regulate DARS. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[29] Dana A. Alqudah,et al. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes , 2020, Breast Cancer.
[30] W. Zheng,et al. LncRNA DARS-AS1 regulates microRNA-129 to promote malignant progression of thyroid cancer. , 2019, European review for medical and pharmacological sciences.
[31] L. Jie,et al. Recent treatment progress of triple negative breast cancer. , 2019, Progress in biophysics and molecular biology.
[32] Jenifer R Prosperi,et al. APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cells , 2019, Neoplasia.
[33] Sajjad Karim,et al. Nanoparticles-based drug delivery and gene therapy for breast cancer: recent advancements and future challenges. , 2019, Seminars in cancer biology.
[34] W. Duan,et al. Exosomes and Nanoengineering: A Match Made for Precision Therapeutics , 2019, Advanced materials.
[35] Wei Tao,et al. ROS‐Responsive Polymeric siRNA Nanomedicine Stabilized by Triple Interactions for the Robust Glioblastoma Combinational RNAi Therapy , 2019, Advanced materials.
[36] Haibo Liu,et al. Long non-coding RNA DARS-AS1 promotes tumorigenesis of non-small cell lung cancer via targeting miR-532-3p. , 2019, Minerva medica.
[37] F. Zhan,et al. Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy , 2019, Haematologica.
[38] Z. Gil,et al. Exosomes and their role in tumorigenesis and anticancer drug resistance. , 2019, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[39] E. Fattal,et al. Aptamer‐guided nanomedicines for anticancer drug delivery , 2018, Advanced drug delivery reviews.
[40] E. Crescenzi,et al. Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications. , 2018, Biochimica et biophysica acta. Reviews on cancer.
[41] E. Crescenzi,et al. Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers , 2017, Scientific Reports.
[42] Liuting Mo,et al. Aptamer-integrated DNA nanostructures for biosensing, bioimaging and cancer therapy. , 2016, Chemical Society reviews.
[43] Walhan Alshaer,et al. Functionalizing Liposomes with anti-CD44 Aptamer for Selective Targeting of Cancer Cells. , 2015, Bioconjugate chemistry.
[44] Louai Labanieh,et al. Nucleic acid aptamers in cancer research, diagnosis and therapy. , 2015, Chemical Society reviews.
[45] T. Anchordoquy,et al. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[46] J. Balko,et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. , 2013, The Journal of clinical investigation.
[47] Hiroshi I. Suzuki,et al. Autophagy is activated by TGF-beta and potentiates TGF-beta-mediated growth inhibition in human hepatocellular carcinoma cells. , 2009, Cancer research.
[48] Wei He,et al. Insight on Multidrug Resistance and Nanomedicine Approaches to Overcome MDR. , 2020, Critical reviews in therapeutic drug carrier systems.
[49] Gong Cheng,et al. Aptamer-Conjugated Extracellular Nanovesicles for Targeted Drug Delivery. , 2018, Cancer research.
[50] W. Gradishar,et al. Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. , 2017, Cancer treatment reviews.